Breaking News, Collaborations & Alliances

BMS, Nissan Chemical, Teijin Pharma Enter Heart Drug Pact

Bristol-Myers Squibb entered a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Ltd. for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), curr

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb entered a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Ltd. for the development and commercialization of NTC-801, a selective inhibitor of the acetylcholine-activated potassium ion channel (IKACh), currently in Phase I development in Japan for the maintenance of normal sinus rhythm in patients with atrial fibrillation. Nissan and Teijin will grant BMS exclusive, worldwide (ex-Japan) rights for NTC-801 and certain backup compounds. BMS will ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters